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INTRODUCTION
Spinal cord injury (SCI) can lead to permanent disability and decreased life expectancy. The primary injury (local damage to tissues) is followed by secondary injuries (neuropathic pain, inflammation, reversible and/or irreversible damage to the nervous system), making SCI difficult to manage [1] [2] [3] [4] . The management of pain and inflammation is achieved using various analgesics and anti-inflammatory agents, including opioids, non-steroidal anti-inflammatory drugs, muscle relaxants, and steroids [4] [5] [6] .
Acute steroid administration has been reported to be effective as a first-line therapy, and a high dose of methylprednisolone (MP) immediately after traumatic SCI is well accepted as a standard treatment [6, 7] . MP is a potent antiinflammatory glucocorticoid. It leads to significant recovery from primary tissue damage and secondary neuropathic pain and inflammation in SCI. MP use has been reported to significantly improve motor nerve activity in cases of SCI [8] [9] [10] .
Although several studies have documented significant positive effects of MP (when administered intravenously) in SCI, many drugs used for the treatment of this condition cannot cross the blood-spinal cord barrier. Thus, neither oral nor intravenous delivery provides the optimal desired benefit of neuroprotective or neuroregenerative drugs. The physical inaccessibility of the spinal cord is usually dealt with using alternative measures, such as local epidural or intrathecal delivery (by bolus injection or catheter/implant insertion) [11, 12] . The delivery of drugs to the microenvironment of the spinal cord through intrathecal administration in polymeric hydrogels and in situ has been reported to be promising in SCI, with advantages including improved safety, prolonged delivery (up to 4 weeks), and reduced dosage (frequency) [13] [14] [15] .
Implants that are formed from polymeric gels or solutions containing drugs undergo chemical or physical changes to form unit implants for controlled drug delivery when injected into the body. Dunn et al [16] were pioneers in the development of in situ implants. Injectable in situ implants of antibiotics were prepared for the local treatment of periodontitis. These systems form implants in situ with changes in factors such as temperature, pH, ionic crosslinking, and solvent removal. Among the various techniques, in situ solvent removal systems have been investigated for the delivery of drugs such as leuprolide acetate (Luteinizing hormone releasing hormone or LHRH agonist) in prostate cancer management, using N-methyl-pyrrolidone (NMP) as the solvent [17, 18] .
The present study concerns the preparation of an in situ hydrogel of MP with polylactide glycolic acid (PLGA) using NMP as a biocompatible solvent (class 2 solvent in the International Conference on Harmonization (ICH) guidelines, with no inflammatory property in biological systems) [19] . NMP is a common organic solvent used in the preparation of in situ PLGA implants. In an in situ solvent removal system, MP is converted to a gel upon contact with the aqueous environment of biological fluids. Immediately after contact with the aqueous environment, the NMP diffuses out rapidly, leading to rapid polymer precipitation. This process ultimately results in the formation of a porous polymer matrix, which then slowly releases the drug [20] . In situ gels can be used for local and systemic controlled drug delivery [14, 15, [21] [22] [23] . Here, we describe the development of a polymeric in situ hydrogel of MP for intrathecal delivery to improve neuroprotective and neuroregenerative effects in SCI.
EXPERIMENTAL Materials
MP succinate, PLGA, and NMP were purchased from Sigma Aldrich, St. Louis, MO, USA). All other chemicals were of analytical grade.
Preparation of polymeric hydrogels of MP
The in situ solvent removal systems for polymeric hydrogels of MP were prepared using the formulae shown in Table 1 . The polymeric solution was prepared with sufficient NMP to dissolve the PLGA at 50°C, and the solution was then cooled to room temperature (25°C). The required amount of drug was weighed accurately and then gently dispersed in the polymeric solution with stirring (200 rpm) for 30 min. After degassing, the resulting solution was sterilized by membrane filtration and then stored in a tightly closed glass vial (10 mL) in a vacuum desiccator.
Physical characterization of the gel implants
The prepared drug-loaded polymeric solutions were observed to evaluate clarity (visual inspection) and viscosity (Brookfield viscometer).
Drug content determination
From the vials of the formulations, 1 mL of each sample was transferred to a volumetric flask using a micropipette. To this sample, methanol (up to 10 mL) was added until complete precipitation (i.e., the upper solution became mostly clear). After centrifugation (1000 rpm, 20 min), the clear supernatant sample was withdrawn. The withdrawn sample was analyzed spectrophotometrically at 246 nm after suitable dilution.
In vitro drug release studies
The formulation (10 mL) was first converted to a hydrogel by mixing with 20 mL phosphate buffer (pH 7.4). Due to the removal of NMP, the hydrogel formed; this pre-gelled hydrogel was then used for the in vitro release study. The study was performed by keeping the pregelled formulation in a glass vial containing another 20 mL phosphate buffer. The vial was kept on a shaker in a water bath at 37 ± 1 °C and 50 oscillations/min. Samples (1 mL each) were withdrawn at predetermined intervals for 7 days. Each sample was replaced with an equal volume of fresh phosphate buffer. The samples (n = 3) were analyzed spectrophotometrically at 246 nm after suitable dilution.
In vivo study protocols
Healthy male Wistar rats (weighing 175 -250 g) were used. The rats were kept in cages in standard environmental conditions of light and temperature. The rats were allowed free access to drinking water and a standard diet. All four formulations were used in the in vivo studies. 
In vivo anti-inflammatory study
The formulations were used in an in vivo antiinflammatory study using the standard carrageenan-induced hind rat paw edema model. Rats were divided into eight groups of six rats each (total, 48 rats). Rats in the control group (group I) remained untreated. In groups II-V, test formulations of polymeric in situ gels were injected (30 mg/kg body weight, ip) into the left hind paws of the rats. Group VI received 2 % indomethacin gel (standard). Paw edema was induced at 30 min after the injection of 0.1 mL of a 1 % (w/v) aqueous suspension of carrageenan in the left hind paw in all rats. The left hind paw volume was measured immediately (0 h) and at subsequent timepoints (0.5, 1, 2, 4, 6, 8, 10, 12, and 24 h) using a plethysmometer, and expressed as percent edema relative to the initial hind paw volume. Percent inhibition of edema was determined and taken as a measure of antiinflammatory activity.
In vivo motor function activity
In total, 42 rats were used. They were divided into four groups (normal control, negative control, standard, and test), with 6 rats each in first three groups and 24 rats in the test group. The test group was further subdivided into four groups of six rats each for the four formulations. All animals (except those in the normal control group) were subjected to laminectomy by inducing acute spinal injury via extradural 40-g-force clip compression for 10 s around T7 after the administration of thiopental sodium (40 mg/kg). A blank (non-medicated) polymeric solution was administered to normal control rats. The test groups received the drug-loaded polymeric in situ gels (30 mg/kg body weight, on the basis of several previous studies) i.t. near the site of the injury. The standard group received MP (30 mg/kg body weight) i.v. at 30 min post-injury. The treatment was continued for 1 week. At the end of 7 days, motor functional activity was determined by observing the performance of rats in a horizontal bar experiment. The time period for which the rat could hold the horizontal bar (2-mm diameter) was noted and scores were given.
Statistical analysis
Results are expressed as means ± standard deviations. Student's t test was used. P values < 0.05 were considered to indicate statistical significance.
RESULTS
On visual inspection, a translucent matrix was formed on addition to phosphate buffer (pH 7.4). The prepared in situ hydrogels were transparent at all pHs tested. The pHs of all formulations were within the acceptable range (Table 2) . The formulations were colorless with good clarity. The drug content of the formulations ranged from 99.00 to 100.01 % ( Table 2) .
Rheological properties
The viscosity of the formulations showed pseudo-plastic rheology, indicated by the shear thinning properties of the formulations. The shear rate increased in direct proportion to the angular velocity in the pregelled formulations. The polymeric solutions showed good syringeability and injectability, facilitating administration. The viscosity was dependent on the polymeric content of the formulations (Figure 1 ).
In vitro drug release
In vitro drug release studies were carried out for all formulations using phosphate buffer (pH 7.4) as the dissolution medium. Drug release values for formulations F1, F2, F3, and F4 were 99.67, 95.29%, 88.89 and 88.20, respectively, at the end of 7 days (Figure 2 ).
The formulation with more PLGA showed slower release of the drug at each timepoint, compared with formulations containing less PLGA. This effect was particularly significant in the initial 6 h for F3 and F4.
In vivo anti-inflammatory activity
The anti-inflammatory activities of all formulations of the polymeric in situ hydrogel of MP were evaluated in Wistar rats (Table 3 ). Inhibition of paw edema was used as an index of anti-inflammatory activity. It was highest for F1 (62.85 %). The rank order of activity was F1 > F2 > F3 > F4. An in vivo study was also performed to assess the effectiveness of motor nerve activity post-trauma in Wistar rats. The F1 group showed better recovery from spinal injury in terms of improved activity score. Despite showing lesser effects than the other two groups, F3 and F4 showed better activity scores (4.68 ± 0.02 and 4.60 ± 0.05, respectively) than the standard (4.59 ± 0.20; Table 4 ). 
DISCUSSION
In situ hydrogels of MP showed good drug content and rheological properties, and formulations with higher polymer concentrations showed greater viscosity. The higher-viscosity polymeric formulations showed slower in vitro drug release, likely due to the formation of a stiffer in situ gel. In situ gel stiffness is related positively to the height of is the diffusional barrier faced by the drug. Previous reports showed that higher concentrations of polymer delayed the onset of release from the formulation due to the retardation of polymer precipitation [22] [23] [24] .
The formulations showed better in vivo performance, indicated by increased antiinflammatory activity and motor function activity in Wistar rats, compared with the corresponding standards. Formulations F1, F2, F3, and F4 showed in vivo performance in terms of motor function activity according to their polymeric content. Those with higher polymeric content showed less total drug release up to day 7, so the effects were smaller. However, even the formulation with the least effect (F4) was better than the standard. As the aim of the study was to prepare a prolonged drug delivery system showing a desired effect in SCI, formulations F3 and F4 are the best candidates for further translational studies.
CONCLUSION
Biodegradable polymers can be used in developing implants as in situ gels of MP for prolonged delivery and effective management of pain and inflammation in SCI. The in situ gels prepared from PLGA using NMP as the solvent showed good in vivo anti-inflammatory activity and effectively improved rat motor function activity. The formulations possessed good physicochemical properties and prolonged drug release, for up to 7 days. Thus, gel implants of MP may be useful as an alternative approach for the effective management of SCI.
